ClinicalTrials.gg
CompletedNCT03358563Updated May 3, 2024

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

An Early Phase 1 interventional study of Docetaxel and Degarelix in Prostate Cancer, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by University of Wisconsin, Madison · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison — 5 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · University of Wisconsin, Madison.

Enrollment
14th of 33
30 · median 30
Started
2018
with 2 others
Phase 1
10 of 38
2 open now
Registered
28th of 38
by date

Among the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 1, and was the 28th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

This is a pilot multimodality treatment approach trial with androgen deprivation therapy in combination with docetaxel chemotherapy followed by radical prostatectomy in patients with newly diagnosed high-risk and oligometastatic prostate cancer. This study aims to evaluate the rates of complete pathologic response (pCR) at the time of prostatectomy as well as PSA response, time to PSA recurrence and safety and toxicity of the combination. This study will be heavily embedded with biomarker analyses of the tumor and tumor cells in circulation as well in the bone marrow before and after treatment and will also include imaging analyses using a novel positron emission tomography (PET) imaging technology.

Read the detailed description

Per a protocol amendment approved on 9/5/2019 - two ferumoxytol MRI scans were added for 3 participants, represented here as an additional arm.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Prostatectomy
  • Chemohormonal therapy
  • Androgen deprivation therapy
  • docetaxel chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate without signet cell or small cell features.
  • High risk prostate cancer defined as extracapsular extension (cT3a) or seminal vesicle involvement (cT3b) or invasion of adjacent structures (cT4), serum PSA greater than 20 ng/mL or Gleason score of 8 to 10 and/or regional lymph node or
  • Oligometastatic disease defined as disseminated beyond regional lymph nodes that meet the following criteria:

    • No visceral metastases
    • Less than four bony metastases.
  • Ability to comply with all study procedures and willingness to remain supine for 120 minutes during imaging.
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written form indicating such an understanding.
  • (ECOG) performance status of 0 or 1 at screening.
  • Patients must be considered candidates for prostatectomy as per standard of care.
  • Adequate hematologic and renal function as evidenced by the following within 4 weeks of day 1:

    • ANC greater than or equal to 1500/mm3
    • (HgB) greater than or equal to 10.0 gr/dL independent of transfusion
    • greater than or equal to 100,000/mm3
    • Creatinine less than or equal to 2.0 mg/dL
    • Total less than or equal to (ULN)
  • Estimated of greater than or equal to 12 months at screening.
  • Throughout the study, patient and his female partner who is of must use 2 acceptable methods of (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after last dose of study drug. Two acceptable methods of birth control thus include the following:

    • A condom (barrier method of contraception) AND One of the following is required:
    • Established and ongoing use of oral, injected, or implanted hormonal method of contraception by the female partner
    • Placement of an intrauterine device or intrauterine system by the female partner
    • Additional barrier method: Contraceptive sponge or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner
    • Tubal ligation in the female partner performed at least 6 months before screening
    • Vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy), performed at least 6 months before screening
  • While receiving chemotherapy, the patient must use a condom if having sex with a pregnant woman.
  • Must agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for prostate cancer, including ADT, orchiectomy, antiandrogens, ketoconazole, abiraterone acetate or enzalutamide.
  • Prior radiation to the prostate.
  • Use of other agent for prostate cancer.
  • No active secondary
  • Chronic liver disease or abnormal liver function:

    • Total greater than (NOTE: in subjects with Gilbert's syndrome, if total bilirubin is greater than ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal range, subject may be eligible) or
    • Alanine () or aspartate (AST) aminotransferase greater than 2.0 x ULN or
    • ALT or aspartate AST greater than 1.5 x ULN concomitant with alkaline phosphatase greater than 2.5 x ULN.
  • Peripheral neuropathy grade greater than 1.
  • Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within the previous 6 months.
  • Major surgery within 4 weeks before screening.
  • Patients with known psychological or sociological conditions, addictive disorders or family problems, which would preclude compliance with the protocol.
  • Herbal supplements that have been shown to modulate testosterone or androgen signaling (e.g. Saw Palmetto) are not allowed while on study.
  • Subjects may not be enrolled concurrently on other treatment studies. Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial; places the patient at undue risk; or complicates the interpretation of the data, in the opinion of the investigator or medical monitor.
  • Subjects who will be receiving Ferumoxytol MRI tracer must:

    • Not have any known to Feraheme or any of its components
    • Must not have a history of allergic reaction to any intravenous iron product.
    • Must not have a known iron overload (based on medical history)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Degarelix SC + bicalutamide + docetaxel

    Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3

    Drug: Docetaxel · Drug: Degarelix · Drug: Bicalutamide

  • Experimental
    DegarelixSC + bicalutamide + docetaxel + Ferumoxytol enhanced MRI

    Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.

    Drug: Docetaxel · Drug: Degarelix · Drug: Bicalutamide · Radiation: Ferumoxytol-enhanced MRI imaging

Interventions

  • Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.

    Also known as: docetaxel chemotherapy, taxotere, PR 56976, NSC #628503

  • Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)

    Also known as: Degarelix acetate

  • The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.

    Also known as: Casodex

  • RadiationFerumoxytol-enhanced MRI imaging

    Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.

06

What researchers measure

Primary outcomes

  1. Change in pCR rates

    Evaluate the pathologic complete response (pCR) rates in the primary tumor from patients with newly diagnosed locally advanced or oligometastatic prostate cancer treated with combination androgen deprivation therapy (ADT) and 3 cycles of docetaxel chemotherapy followed by prostatectomy.

    Time frame: Up to 6 months

Secondary outcomes

  1. Change in PSA

    Evaluate the percentage of change in prostate-specific antigen (PSA) from baseline (3 months prior to prostatectomy) to week 6 after prostatectomy in patients with newly diagnosed locally advanced or oligometastatic prostate cancer treated with combination ADT and docetaxel as well as the maximum decline in PSA that occurs at any point during treatment.

    Time frame: From baseline (3 months prior to prostatectomy) to 4-6 weeks after prostatectomy.

  2. PSA Recurrence

    Rate of patients with PSA recurrence at month 12 after surgery

    Time frame: Up to 12 months

  3. Safety and tolerability of combination ADT and docetaxel measured by CTCAE v.4.0

    Evaluate safety and tolerability of the combination of ADT and docetaxel for up to three months following the last dose of docetaxel.

    Time frame: Up to 6 months

Other outcomes

  1. Evaluating PSMA PET/MRI imaging

    Evaluate PSMA PET/MRI imaging as a method for determining treatment response in primary prostate cancer and metastatic lesions after ADT and docetaxel.

    Time frame: Up to 12 months

  2. Evaluating Response Heterogeneity

    Evaluate heterogeneity of response in multifocal prostate lesions at the time the primary objective is assessed

    Time frame: Up to 6 months

  3. Change in total tumor burden in individual lesions

    Evaluate change in total tumor burden in individual lesions and across all lesions over time for each patient

    Time frame: Up to 12 months

  4. Evaluating immune microenvironment in prostate with ferumoxytol-enhanced MRI relaxometry

    Evaluate immune microenvironment in prostate with ferumoxytol-enhanced MRI relaxometry

    Time frame: Up to 12 months

  5. Disease progression

    Correlate disease progression on MRI, technetium Tc 99m medronate (99mTc-MDP) bone scintigraphy and CT scans with PSMA uptake measures

    Time frame: Up to 12 months

  6. PSMA PET results and PSA response correlation

    Correlate prostate-specific membrane antigen (PSMA) PET results with PSA response and time to PSA progression

    Time frame: Up to 12 months

  7. Evaluate genomic signatures in multifocal prostate cancer after ADT and Docetaxel

    Prostate cancer cells extracted from the prostatectomy specimen will undergo nucleic acid extraction. DNA will be isolated and sequenced using the Foundation Medicine Next Generation Sequencing platform or other genomic panels

    Time frame: Up to 12 months

  8. Evaluate gene expression signatures in multifocal prostate cancer after ADT and Docetaxel

    Prostate cancer cells will be extracted from the prostatectomy specimen and undergo nucleic acid extraction. mRNA will be isolated and analyzed with gene expression panels with quantitative RT PCR and/or next generation sequencing.

    Time frame: Up to 12 months

  9. Evaluate gene expression signatures in prostate stroma after ADT and Docetaxel

    Prostate stromal cells will be extracted from the prostatectomy specimen and undergo nucleic acid extraction. mRNA will be isolated and analyzed with gene expression panels with quantitative RT PCR and/or next generation sequencing.

    Time frame: Up to 12 months

  10. Evaluate infiltrating immune cells in prostatectomy specimens after ADT and Docetaxel

    Immune cells will be extracted from the prostatectomy specimen and bone marry biopsies. These cells are labelled with antibodies and quantified using flow cytometry.

    Time frame: Up to 12 months

  11. Evaluating EpCAM-positive disseminated and circulating tumor cells

    Evaluate epithelial cell adhesion molecule (EpCAM)-positive disseminated and circulating tumor cells for subcellular localization of the androgen receptor and glucocorticoid receptor

    Time frame: Up to 12 months

  12. Disseminated and circulating tumor cell analyses versus PSMA PET/MRI and clinical outcomes

    Correlate disseminated and circulating tumor cell analyses with the PSMA PET/MRI measures and clinical outcomes.

    Time frame: Up to 12 months

  13. Evaluate immune microenvironment in bone marrow after ADT and Docetaxel

    Immune cells will be extracted from the prostatectomy specimen and bone marrow biopsies.

    Time frame: Up to 12 months

  14. Evaluate secretory profile of stroma after ADT and Docetaxel

    Prostate stromal cells will be extracted from the prostatectomy specimen and undergo nucleic acid extraction.

    Time frame: Up to 12 months

  15. Evaluate immune microenvironment in prostate after ADT and Docetaxel

    Evaluating immune microenvironment in prostate by assessing protein and molecular biomarkers after ADT and Docetaxel. Archival formalin-fixed-paraffin-embedded prostate tissue will be used for this aim.

    Time frame: Up to 12 months

07

Study locations

1 site
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2021, 42 months.

Of 244 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's 42 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Nov 30, 2017
StartActual
Jan 17, 2018
Primary completionActual
Aug 10, 2021
CompletionActual
Sep 2, 2022
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03358563
Collaborators
United States Department of Defense, Prostate Cancer Foundation
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Jan 17, 2018
Primary completion
Aug 10, 2021
Completion
Sep 2, 2022
Last update
May 3, 2024

Study contacts

Christos Kyriakopoulos, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion